Effects of ketamine on psychomotor, Sensory and cognitive functions relevant for driving ability

Forensic Science International

Volumn 252, Issue , 2015, Pages 127-142

  Giorgetti, R ^a   Marcotulli, D ^a   Tagliabracci, A ^a   Schifano, F ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Cognitive deterioration; Drug misuse; Drugs and driving; Ketamine

Indexed keywords

DEXTROMETHORPHAN; KETAMINE; ANESTHETIC AGENT;

ALERTNESS; ATTENTION; ATTENTION DISTURBANCE; BEHAVIOR; CEREBELLUM DISEASE; COGNITION; DELUSION; DISTRACTIBILITY; DRIVING ABILITY; DRUG ABUSE; DRUG DETERMINATION; DRUG MISUSE; EXECUTIVE FUNCTION; EYE MOVEMENT; HALLUCINATION; HUMAN; MOTOR PERFORMANCE; PERCEPTION; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR RETARDATION; RECREATION; REVIEW; TIME PERCEPTION; TRAFFIC ACCIDENT; VISION; WORKING MEMORY; CHEMICALLY INDUCED; COGNITIVE DEFECT; DISSOCIATIVE DISORDER; DRUG DEPENDENCE; DRUG EFFECTS; DRUNKEN DRIVING; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SHORT TERM MEMORY;

ANESTHETICS, DISSOCIATIVE; ATTENTION; COGNITION DISORDERS; DISSOCIATIVE DISORDERS; DRIVING UNDER THE INFLUENCE; HALLUCINATIONS; HUMANS; KETAMINE; MEMORY, SHORT-TERM; PERCEPTION; PSYCHOMOTOR PERFORMANCE; SUBSTANCE-RELATED DISORDERS;

EID: 84929327150     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2015.04.024     Document Type: Review

References (151)

1. Schifano F., Corkery J., Oyefeso A., Tonia T., Ghodse A. Trapped in the K-hole: overview of deaths associated with ketamine misuse in the UK (1993-2006). J. Clin. Psychopharmacol. 2008, 28:114-116.
2. Corazza O., Schifano F., Simonato P., Fergus S., Assi S., Stair J., et al. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum. Psychopharmacol. 2012, 27:145-149.
3. Chiappini S., Claridge H., Corkery J., Gimeno Clemente C., Goodair C., Loi B., Schifano F. Special Mrelated fatalities in the UK. Res. Adv. Psychiatry 2014, 1:p38.
4. Sanacora G., Schatzberg A.F. Ketamine promising path or false prophecy in the development of novel therapeutics for mood disorders?. Neuropsychopharmacology 2015, 40:259-267.
5. Wolff K., Winstock A.R. Ketamine: from medicine to misuse. CNS Drugs 2006, 20:199-218.
6. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) Risk assessments ketamine. Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. Lisbon, 2002 2002, http://www.emcdda.europa.eu/attachements.cfm/att_33342_EN_Risk3.pdf.
7. Degenhardt L., Copeland J., Dillon P. Recent trends in the use of club drugs: an Australian review. Subst. Use Misuse 2005, 40:1241-1256.
8. United Nations Office on Drugs and Crime Amphetamines and Ecstasy: 2008 Global ATS Assessment 2008, http://www.unodc.org/.
9. Kalsi S.S., Wood D.M., Dargan P.I. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg. Health Threats J. 2011, 4:7107-7114.
10. De Luca M.T., Meringolo M., Spagnolo P.A., Badiani A. The role of setting for ketamine abuse: clinical and preclinical evidence. Rev. Neurosci. 2012, 23:769-780.
11. The European Monitoring Centre for Drugs and Drug Addiction - European Drug Report 2013: trends and developments. Euro Surveill. 2013, 18.
12. ACMD (Advisory Council on the Misuse of Drugs) Ketamine: A Review of Use and Harm December, 2013, ACMD, London. http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/264677/ACMD_ketamine_report_dec13.pdf.
13. Maxwell J.C. Party drugs: properties, prevalence, patterns, and problems. Subst. Use Misuse 2005, 40:1203-1240.
14. Muetzelfeldt L., Kamboj S.K., Rees H., Taylor J., Morgan C.J., Curran H.V. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008, 95:219-229.
15. Jones A., Kugelberg F., Holmgren A., Ahlner J. Five-year update on the occurrence of alcohol and other drugs in blood samples from drivers killed in road-traffic crashes in Sweden. Forensic Sci. Int. 2009, 186:56-62.
16. Zhuo X., Cang Y., Yan H., Bu J., Shen B. The prevalence of drugs in motor vehicle accidents and traffic violations in Shanghai and neighboring cities. Accid. Anal. Prev. 2010, 42:2179-2184.
17. Wolff K., Brimblecombe R., Forfar J.C., Forrest A.R., Gilvarry E., Johnston A., Morgan J., Osselton M.D., Read L., Taylor D. Expert Panel on Drug Driving 2013, Department for Transport, Great Minister House, London.
18. Chu M., Gerostamoulos D., Beyer J., Rodda L., Boorman M., Drummer O.H. The incidence of drugs of impairment in oral fluid from random roadside testing. Forensic Sci. Int. 2012, 215(1):28-31.
19. Burch H.J., Clarke E.J., Hubbard A.M., Scott-Ham M. Concentrations of drugs determined in blood samples collected from suspected drugged drivers in England and Wales. J. Forensic Leg. Med. 2013, 20:278-289.
20. Bezemer K., Smink B., Maanen R., Verschraagen M., de Gier J. Prevalence of medicinal drugs in suspected impaired drivers and a comparison with the use in the general Dutch population. Forensic Sci. Int. 2014, 241:203-211.
21. Wong O.F., Tsui K.L., Lam T.S., Sze N.N., Wong S.C., Lau F.L., Liu S.H. Prevalence of drugged drivers among non-fatal driver casualties presenting to a trauma centre in Hong Kong. Hong Kong Med. J. 2010, 16:246-251.
22. Cheng J.Y., Chan D.T., Mok V.K.K. An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000. Forensic Sci. Int. 2005, 153:196-201.
23. Ferrara S.D., Giorgetti R., Zancaner S. Psychoactive substances and driving state of the art and methodology. Alcohol Drugs Driv. 1994, 10:1-56.
24. Waelbers T., Polis I., Vermeire S., Dobbeleir A., Eersels J., De Spiegeleer B., Audenaert K., Slegers G., Peremans K. 5-HT2A receptors in the feline brain: 123I-5-I-R91150 kinetics and the influence of ketamine measured with micro-SPECT. J. Nucl. Med. 2013, 54:1428-1433.
25. Anis N., Berry S., Burton N., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 1983, 79:565-575.
26. Nishimura M., Sato K. Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci. Lett. 1999, 274:131-134.
27. Klepstad P., Maurset A., Moberg E.R., Øye I. Evidence of a role for NMDA receptors in pain perception. Eur. J. Pharmacol. 1990, 187(3):513-518.
28. Oye I., Paulsen O., Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-d-aspartate receptors. J. Pharmacol. Exp. Ther. 1992, 260:1209-1213.
29. Smith J.W., Gastambide F., Gilmour G., Dix S., Foss J., Lloyd K., Malik N., Tricklebank M. A comparison of the effects of ketamine and phencyclidine with other antagonists of the nmda receptor in rodent assays of attention and working memory. Psychopharmacology (Berlin) 2011, 217(2):255-269.
30. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
31. Carter A.J. Antagonists of the nmda receptor-channel complex and motor coordination. Life Sci. 1995, 57(10):917-929.
32. Hustveit O., Maurset A., Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol. Toxicol. 1995, 77:355-359.
33. Mion G., Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci. Ther. 2013, 19:370-380.
34. da Fonseca Pacheco D., Romero T.R.L., Duarte I.D.G. Central antinociception induced by ketamine is mediated by endogenous opioids and μ-and δ-opioid receptors. Brain Res. 2014, 1562:69-75.
35. Gupta A., Devi L.A., Gomes I. Potentiation of μ-opioid receptor-mediated signaling by ketamine. J. Neurochem. 2011, 119(2):294-302.
36. Kohrs R., Durieux M.E. Ketamine: teaching an old drug new tricks. Anesth. Analg. 1998, 87(5):1186-1193.
37. Vollenweider F.X., Vontobel P., Oye I., Hell D., Leenders K.L. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J. Psychiatr. Res. 2000, 34:35-43.
38. White J.M., Ryan C.F. Pharmacological properties of ketamine. Drug Alcohol Rev. 1996, 15:145-155.
39. Duan T.T., Tan J.W., Yuan Q., Cao J., Zhou Q.X., Xu L. Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine d1/d5 receptors. Psychopharmacology (Berlin) 2013, 228(3):451-461.
40. Aalto S., Ihalainen J., Hirvonen J., Kajander J., Scheinin H., Tanila H., Någren K., Vilkman H., Gustafsson L.L., Syvälahti E., Hietala J. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berlin) 2005, 182(3):375-383.
41. Seeman P., Ko F., Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol. Psychiatry 2005, 10(9):877-883.
42. Dalgarno P.J., Shewan D. Illicit use of ketamine in Scotland. J. Psychoact. Drugs 1996, 28:191-199.
43. Barceloux D.G. Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants 2012, 111. Wiley & Sons, Hoboken.
44. Yanagihara Y., Ohtani M., Kariya S., Uchino K., Hiraishi T., Ashizawa N., Aoyama T., Yamamura Y., Yamada Y., Iga T. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm. Drug Dispos. 2003, 24:37-43.
45. Malinovsky J., Servin F., Cozian A., Lepage J., Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br. J. Anaesth. 1996, 77:203-207.
46. Chong C., Schug S., Page-Sharp M., Ilett K. Bioavailability of ketamine after oral or sublingual administration. Pain Med. 2006, 7:p469.
47. Grant I.S., Nimmo W.S., Clements J.A. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br. J. Anaesth. 1981, 53:805-810.
48. Kronenberg R.H. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J. Pain Palliat. Care Pharmacother. 2002, 16:27-35.
49. Hijazi Y., Boulieu R. Protein binding of ketamine and its active metabolites to human serum. Eur. J. Clin. Pharmacol. 2002, 58:37-40.
50. Hijazi Y., Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 2002, 30:853-858.
51. Ebert B., Mikkelsen S., Thorkildsen C. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur. J. Pharmacol. 1997, 333:99-104.
52. Olofsen E., Noppers I., Niesters M., Kharasch E. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology 2012, 117:353-364.
53. Moffat A.C., Osselton D.M., Widdop B. Clarke's Analysis of Drugs and Poisons 2011, 1539-1540. Pharmaceutical Press, London.
54. Bowdle A., Radant A., Cowley D., Kharasch E., Strassman R., Roy-Byrne P. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998, 88:82-88.
55. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
56. Dillon P., Copeland J., Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003, 69:23-28.
57. Jansen K. Ketamine: Dreams and Realities 2011, Multidisciplinary Association for Psychedelic Studies, Sarasota.
58. Adell A., Jiménez-Sánchez L., López-Gil X., Romón T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?. Schizophr. Bull. 2012, 38:9-14.
59. Felser J.M., Orban D.J. Dystonic reaction after ketamine abuse. Ann. Emerg. Med. 1982, 11:673-675.
60. Corlett P.R., Honey G.D., Krystal J.H., Fletcher P.C. Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology 2011, 36:294-315.
61. Corkery J., Claridge H., Loi B., Goodair C., Schifano F. Drug Related Deaths in the UK. NPSAD Annual Report 2013 2014, International Centre for Drug Policy, St George's, University of London, London.
62. Morgan C.J., Monaghan L., Curran H.V. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004, 99:1450-1461.
63. Luciano R.L., Perazella M.A. Nephrotoxic effects of designer drugs: synthetic is not better!. Nat. Rev. Nephrol. 2014, 10:314-324.
64. Ng S., Tse M., Ng H., Lau F.L. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med. J. 2010, 16(1):6-11.
65. Cheung R., Chan S., Lee J., Pang A., Choy K., Chung T. Urinary symptoms and impaired quality of life in female ketamine users: persistence after cessation of use. Hong Kong Med. J. 2011, 17(4):267-273.
66. Tam Y.H., Ng C.F., Pang K.K.Y., Yee C.H., Chu W.C.W., Leung V.Y.F., Wong G.L.H., Wong V.W.S., Chan H.L.Y., Lai P.B.S. One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients' characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. BJU Int. 2014, 114(5):754-760.
67. Ng C., Ma W., To K., Yiu M. The Chinese version of the pelvic pain and urgency/frequency symptom scale: a useful assessment tool for street-ketamine abusers with lower urinary tract symptoms. Hong Kong Med. J. 2012, 18(2):123-130.
68. Centini F., Gabbrielli M., Fineschi V., Comparini B.I. Fatal ketamine abuse: report of a case and analytical determination by gas liquid chromatography/mass spectrometry. Dev. Anal. Met. Pharmac. Biomed. Forensic Sci. 1987, 147-153.
69. Lalonde B.R., Wallage H.R. Postmortem blood ketamine distribution in two fatalities. J. Anal Toxicol. 2004, 28:71-74.
70. Peyton S.H., Couch A.T., Bost R.O. Tissue distribution of ketamine: two case reports. J. Anal. Toxicol. 1988, 12:268-269.
71. Corazza O., Assi S., Schifano F. From Special K to Special M: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci. Ther. 2013, 19:454-460.
72. Schifano F., Orsolini L., Papanti G.D., Corkery J. Novel psychoactive substances of interest for psychiatry. World Psychiatry 2015, 14:15-26.
73. Corazza O., Schifano F. Near-death states reported in a sample of 50 misusers. Subst. Use Misuse 2010, 45:916-924.
74. Dargan P.I., Tang H.C., Liang W., Wood D.M., Yew D.T. Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin. Toxicol. (Phila) 2014, 52:176-180.
75. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), Risk assessments Methoxetamine Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances. Lisbon 2014.
76. Shields J.E., Dargan P.I., Wood D.M., Puchnarewicz M., Davies S., Waring W.S. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin. Toxicol. 2012, 50(5):438-440.
77. Wood D.M., Davies S., Puchnarewicz M., Johnston A., Dargan P.I. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 2012, 68(5):853-856.
78. Adamowicz P., Zuba D. Fatal intoxication with methoxetamine. J. Forensic Sci. 2015, 60(s1):264-268.
79. Morris H., Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug. Test Anal. 2014, 6:614-632.
80. Chyka P.A., Erdman A.R., Manoguerra A.S., Christianson G., Booze L.L., Nelson L.S., Woolf A.D., Cobaugh D.J., Caravati E.M., Scharman E.J., Troutman W.G. Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin. Toxicol. (Phila.) 2007, 45:662-677.
81. Brown S.D., Melton T.C. Trends in bioanalytical methods for the determination and quantification of club drugs: 2000-2010. Biomed. Chromatogr. 2011, 25:300-321.
82. Wieber J., Gugler R., Hengstmann J.H., Dengler H.J. Pharmacokinetics of ketamine in man. Anaesthesist 1975, 24:260-263.
83. Adamowicz P., Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations. J. Anal. Toxicol. 2005, 29:376-382.
84. Parkin M., Turfus S., Smith N., Halket J., Braithwaite R., Elliott S., Osselton M.D., Cowan D.A., Kicman A.T. Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 876:137-142.
85. Harun N., Anderson R.A., Miller E.I. Validation of an enzyme-linked immunosorbent assay screening method and a liquid chromatography-tandem mass spectrometry confirmation method for the identification and quantification of ketamine and norketamine in urine samples from malaysia. J. Anal. Toxicol. 2009, 33(6):310-321.
86. Hijazi Y., Bolon M., Boulieu R. Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples. Clin. Chem. 2001, 47:1713-1715.
87. Chen C.Y., Lee M.R., Cheng F.C., Wu G.J. Determination of ketamine and metabolites in urine by liquid chromatography-mass spectrometry. Talanta 2007, 72:1217-1722.
88. Bolze S., Boulieu R. HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high-purity reversed-phase sorbent. Clin. Chem. 1998, 44:560-564.
89. Huang M.-H.H., Wu M.-Y.Y., Wu C.-H.H., Tsai J.-L.L., Lee H.-H.H., Liu R.H. Performance characteristics of ELISAs for monitoring ketamine exposure. Clin. Chim. Acta 2007, 379:59-65.
90. Tsui T.K., Chan A.S., Lo C.W., Wong A., Wong R.C., Ho C.S. Performance of a point-of-care device for oral fluid ketamine evaluated by a liquid chromatography-tandem mass spectrometry method. J. Anal. Toxicol. 2012, 36:210-216.
91. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans, psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
92. Harborne G.C., Watson F.L., Healy D.T., Groves L. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J. Psychopharmacol. 1996, 10:134-140.
93. Adler C., Goldberg T., Malhotra A., Pickar D., Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol. Psychiatry 1998, 43:811-816.
94. Krystal J.H., Karper L.P., Bennett A., D'Souza D.C., Abi-Dargham A., Morrissey K., Abi-Saab D., Bremner J.D., Bowers M.B., Suckow R.F., Stetson P., Heninger G.R., Charney D.S. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berlin) 1998, 135:213-229.
95. Krystal J., Bennett A., Abi-Saab D., Belger A., Karper L., D'Souza D.C., Lipschitz D., Abi-Dargham A., Charney D.S. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol. Psychiatry. 2000, 47:137-143.
96. Oranje B., van Berckel B.N., Kemner C., van Ree J.M., Kahn R.S., Verbaten M.N. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology. 2000, 22:293-302.
97. Passie T., Karst M., Wiese B., Emrich H.M., Schneider U. Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology 2005, 51:226-233.
98. Krystal J., Perry E., Gueorguieva R., Belger A., Madonick S., Abi-Dargham A., Cooper T.B., Macdougall L., Abi-Saab W., D'Souza D.C. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry 2005, 62:985-994.
99. Knott V.J., Millar A.M., McIntosh J.F., Shah D.K., Fisher D.J., Blais C.M., Ilivitsky V., Horn E. Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. Biol. Psychol. 2011, 88:83-93.
100. Musso F., Brinkmeyer J., Ecker D., London M., Thieme G., Warbrick T., Wittsack H.J., Saleh A., Greb W.W., de Boer P., Winterer G. Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task. NeuroImage. 2011, 58:508-525.
101. Carter L., Kleykamp B., Griffiths R., Mintzer M. Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology (Berlin) 2013, 226:53-63.
102. Guillermain Y., Micallef J., Possamaï C., Blin O., Hasbroucq T. N-methyl-d-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine. Neurosci. Lett. 2001, 303:29-32.
103. Rogers R., Wise R.G., Painter D.J., Longe S.E., Tracey I. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 2004, 100:292-301.
104. Lofwall M.R., Griffiths R.R., Mintzer M.Z. Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp. Clin. Psychopharmacol. 2006, 14:439-449.
105. Weiler M.A., Thaker G.K., Lahti A.C., Tamminga C.A. Ketamine effects on eye movements. Neuropsychopharmacology 2000, 23:645-653.
106. Avila M.T., Weiler M.A., Lahti A.C., Tamminga C.A., Thaker G.K. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am. J. Psychiatry 2002, 159:1490-1496.
107. Umbricht D., Schmid L., Koller R., Vollenweider F., Hell D., Javitt D. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers. Arch. Gen. Psychiatry 2000, 57:1139-1147.
108. Abel K.M., Allin M.P., Hemsley D.R., Geyer M.A. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 2003, 44:729-737.
109. Pomarol-Clotet E., Honey G.D., Murray G.K., Corlett P.R., Absalom A.R., Lee M., McKenna P.J., Bullmore E.T., Fletcher P.C. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br. J. Psychiatry 2006, 189:173-179.
110. Morgan H.L., Turner D.C., Corlett P.R., Absalom A.R., Adapa R., Arana F.S., Pigott J., Gardner J., Everitt J., Haggard P., Fletcher P.C. Exploring the impact of ketamine on the experience of illusory body ownership. Biol. Psychiatry 2011, 69:35-41.
111. Meuwese J.D., van Loon A.M., Scholte H.S., Lirk P.B., Vulink N.C.C., Hollmann M.W., Lamme V.A. NMDA receptor antagonist ketamine impairs feature integration in visual perception. PLoS ONE 2013, 8:e79326.
112. Coull J.T., Morgan H., Cambridge V.C., Moore J.W., Giorlando F., Adapa R., Corlett P.R., Fletcher P.C. Ketamine perturbs perception of the flow of time in healthy volunteers. Psychopharmacology (Berlin) 2011, 218:543-556.
113. van Berckel B.N., Oranje B., van Ree J.M., Verbaten M.N., Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berlin) 1998, 137:271-281.
114. Duncan E.J., Madonick S.H., Parwani A. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 2001, 25:72-83.
115. Boeijinga P.H., Soufflet L., Santoro F., Luthringer R. Ketamine effects on cns responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man. J. Psychopharmacol. 2007, 21(3):321-337.
116. Curran H., Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000, 95:575-590.
117. Uhlhaas P.J., Millard I., Muetzelfeldt L., Curran H.V., Morgan C.J. Perceptual organization in ketamine users: preliminary evidence of deficits on night of drug use but not 3 days later. J. Psychopharmacol. (Oxford) 2007, 21:347-352.
118. Wilkins L.K., Girard T.A., Cheyne J.A. Anomalous bodily-self experiences among recreational ketamine users. Cogn. Neuropsychiatry 2012, 17:415-430.
119. Taffe M., Davis S., Gutierrez T., Gold L. Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend. 2002, 68:175-187.
120. Stoet G., Snyder L.H. Effects of the NMDA antagonist ketamine on task-switching performance: evidence for specific impairments of executive control. Neuropsychopharmacology 2006, 31:1675-1681.
121. Condy C., Wattiez N., Rivaud-Péchoux S., Gaymard B. Ketamine-induced distractibility: an oculomotor study in monkeys. Biol. Psychiatry 2005, 57:366-372.
122. Floresco S., Tse M., Ghods-Sharifi S. Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharmacology 2007, 33:1966-1979.
123. Amitai N., Markou A. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-d-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol. Psychiatry 2010, 68:5-16.
124. Xu K., Krystal J.H., Ning Y., He H., Wang D., Ke X., Zhang X., Ding Y., Liu Y., Gueorguieva R., Wang Z., Limoncelli D., Pietrzak R.H., Petrakis I.L., Zhang X., Fan N. Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. J. Psychiatr. Res. 2015, 61:64-72.
125. De las Cuevas C., Ramallo Y., Sanz E.J. Psychomotor performance and fitness to drive: the influence of psychiatric disease and its pharmacological treatment. Psychiatry Res. 2010, 176(2):236-241.
126. Twamley E.W., Doshi R.R., Nayak G.V., Palmer B.W., Golshan S., Heaton R.K., Patterson T.L., Jeste D.V. Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am. J. Psychiatry 2002, 159(12):2013-2020.
127. Palmer B.W., Heaton R.K., Gladsjo J.A., Evans J.D., Patterson T.L., Golshan S., Jeste D.V. Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophr. Res. 2002, 55(3):205-215.
128. Soyka M., Winter C., Kagerer S., Brunnauer M., Laux G., Möller H.J. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J. Psychiatr. Res. 2005, 39(1):101-108.
129. Tsakiris M., Haggard P. The rubber hand illusion revisited: visuotactile integration and self-attribution. J. Exp. Psychol. Hum. Percept. Perform. 2005, 31(1):80.
130. Herbert M.J. Analysis of a complex skill: vehicle driving. Hum. Factor Ergon. Soc. 1963, 5(4):363-372.
131. Rockwell T.H. Eye movement analysis of visual information acquisition in driving: an overview. Australian Road Research Board (ARRB) Conference, 6th, 1972, Canberra, vol. 6 1972, 316-331.
132. Thaker G.K., Ross D.E., Cassady S.L., Adami H.M., LaPorte D., Medoff D.R., Lahti A. Smooth pursuit eye movements to extraretinal motion signals: deficits in relatives of patients with schizophrenia. Arch. Gen. Psychiatry 1998, 55(9):830-836.
133. Haarmeier T., Thier P. Impaired analysis of moving objects due to deficient smooth pursuit eye movements. Brain 1999, 122(8):1495-1505.
134. Dahlen E.R., Martin R.C., Ragan K., Kuhlman M.M. Driving anger, sensation seeking, impulsiveness, and boredom proneness in the prediction of unsafe driving. Accid. Anal. Prev. 2005, 37(2):341-348.
135. Verster J.C., Roth T. Predicting psychopharmacological drug effects on actual driving performance (SDLP) from psychometric tests measuring driving-related skills. Psychopharmacology (Berlin) 2012, 220(2):293-301.
136. Ross V., Jongen E.M.M., Wang W., Brijs T., Brijs K., Ruiter R.A., Wets G. Investigating the influence of working memory capacity when driving behavior is combined with cognitive load: an LCT study of young novice drivers. Accid. Anal. Prev. 2014, 62:377-387.
137. Johannsdottir K.R., Herdman C.M. The role of working memory in supporting drivers situation awareness for surrounding traffic. Hum. Factor Ergon. Soc. 2010, 52(6):663-673.
138. Heenan A., Herdman C.M., Brown M.S., Robert N. Effects of conversation on situation awareness and working memory in simulated driving. Hum. Factor Ergon. Soc. 2014, 56(6):1077-1092.
139. Vaucher P., Herzig D., Cardoso I., Herzog M.H., Mangin P., Favrat B. The trail making test as a screening instrument for driving performance in older drivers; a translational research. BMC Geriatr. 2014, 14(1):123.
140. Carr D.B., Duchek J.M., Meuser T.M., Morris J.C. Older adult drivers with cognitive impairment. Am. Fam. Physician 2006, 73(6):1029-1034.
141. Dobbs B.M., Shergill S.S. How effective is the trail making test (parts a and b) in identifying cognitively impaired drivers?. Age Ageing 2013, 42(5):577-581.
142. Marcotte T.D., Grant I. Neuropsychology of Everyday Functioning 2009, Guilford Press.
143. Iwamoto K., Takahashi M., Nakamura Y., Kawamura Y., Ishihara R., Uchiyama Y., Ebe K., Noda A., Noda Y., Yoshida K., Iidaka T., Ozaki N. The effects of acute treatment with paroxe- tine, amitriptyline, and placebo on driving performance and cognitive function in healthy japanese subjects: a double-blind crossover trial. Hum. Psychopharmacol. 2008, 23(5):399-407.
144. Takahashi M., Iwamoto K., Kawamura Y., Nakamura Y., Ishihara R., Uchiyama Y., Ebe K., Noda A., Noda Y., Yoshida K., Iidaka T., Ozaki N. The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers. Hum. Psychopharmacol. 2010, 25(3):260-267.
145. Sasada K., Iwamoto K., Kawano N., Kohmura K., Yamamoto M., Aleksic B., Ebe K., Noda Y., Ozaki N. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. Hum. Psychopharmacol. 2013, 28(3):281-286.
146. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17(3):141-150.
147. Krystal J.H., Petrakis I.L., Limoncelli D., Webb E., Gueorgueva R., D'Souza D.C., Boutros N.N., Trevisan L., Charney D.S. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology 2003, 28:2020-2028.
148. Jansen K. Non-medical use of ketamine. BMJ 1993, 306:601-602.
149. Vindenes V., Jordbru D., Knapskog A.B., Kvan E., Mathisrud G., Slørdal L., Mørland J. Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. Forensic Sci. Int. 2012, 219:1-11.
150. Regulations to Specify the Drugs and Corresponding Limits for the New Offence of Driving with a Specified Controlled Drug in the Body Above The Specified Limit - A Consultation Document Proposed Drugs and Corresponding Limits to be Specified in Regulations Using the Power in Section 5A of the Road Traffic Act 1988 (as inserted by the Crime and Courts Act 2013) 2013, Department of Transport, Great Minister House, London. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/226723/consultation-document.doc.
151. Cheng W.C., Ng K.M., Chan K.K., Mok V.K., Cheung B.K. Roadside detection of impairment under the influence of ketamine-evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine. Forensic Sci. Int. 2007, 170:51-58.